Clinical Studies - Currently Enrolling
The following list contains clinical studies in which HeartCare Midwest is still enrolling patients. For questions or to enroll, please contact our research staff at 309-589-1930. For "Follow-Ups", click here.
BRIDGE: This study is a randomized double-blind, placebo-controlled trial comparing ‘bridging anticoagulation’ with ‘no bridging anticoagulation’ during temporary interruption of warfarin in patients with chronic non valvular or valvular atrial fibrillation or atrial flutter who are receiving warfarin and are undergoing an elective surgical or other invasive procedure. For more information, contact Stephanie (309) 691-4410.
CANOPY: The purpose of the CANOPY trial is to continue to evaluate the safety and effectiveness of the RX Acculink Carotid Stent System, manufactured by Abbott Vascular, in subjects at standard risk for adverse events from carotid Endarterectomy in the commercial setting. The primary outcome measured in the trial is the death and stroke rate. All enrolled subjects will have clinical follow-up office visits up to 3 years. For more information, contact Marsha at (309) 691-4410.
DENALI: The Bard® Denali™ Retrievable Inferior Vena Cava (IVC) study is a prospective, multi-center study which is intended to provide evidence of safety of the placement and retrieval of the Bard® Denali™ Retrievable Inferior Vena Cava Filter in subjects requiring IVC interruption to protect against pulmonary embolism (PE). All subjects enrolled in the study will be followed to 24 months post filter placement or to one month post filter retrieval, whichever occurs first. For more information, contact Gina at (309) 691-4410.
EXCEL: The primary objective of this study is to establish the safety and efficacy of the XIENCE PRIME or XIENCE V Everolimus Eluting Coronary Stent System (EECSS) in subjects with unprotected left main coronary artery (ULMCA) disease (either isolated to the left main trunk or associated with disease in other coronary arteries) by demonstrating that compared to coronary artery CABG, treatment of the left main stenosis ± other significant coronary lesions with the XIENCE PRIME or XIENCE V stent will result in non-inferior or superior rates of the composite measure of all-cause mortality, myocardial infarction or stroke at an anticipated median follow-up duration of three years. Follow-up for all randomized subjects will continue for 5 years with a potential for additional follow-up to 10 years. For more information, contact Rita at (309) 691-4410.
QUAD PAS: The purpose of this post approval study is to evaluate the acute and chronic performance of a St. Jude Medical Quadripolar CRT-D device system in a patient population indicated for cardiac resynchronization therapy. The study will include eligible patients who participated in the St. Jude Medical’s Promote® Q CRT-D and Quartet™ Left Ventricular Heart Lead Study (IDE study), or are receiving a new Quadripolar CRT-D device system implant or are undergoing an upgrade from an existing ICD or pacemaker implant with no prior LV lead placement. Follow up for all new enrolled subjects will be for 5 years. For more information, contact Stephanie at (309) 691-4410.
TRANSLATE ACS: Observational study for Acute Coronary Syndrome (ACS), Non-ST Elevation Myocardial Infarction (NSTEMI) and ST Elevation Myocardial Infarction (STEMI) managed with Percutaneous Intervention (PCI) and initiated on Plavix or Prasugrel. Phone follow-up will be done by Duke Clinical Research Institute. Follow-up will be for 15 months. For more information, contact Rita at (309) 691-4410.
VISIBILITY: This is a prospective, multi-center, non-randomized, clinical study. The objective of the study is to confirm the safety and effectiveness of primary stenting using the Visi-Pro Balloon Expandable Stent System for the treatment of stenotic, restenotic (from PTA or adjunct therapy, not including stents or stent grafts) or occluded lesions of the common and/or external iliac arteries. Follow up evaluations will take place up to 3 years after the procedure. For more information, contact Stephanie at (309) 691-4410.
ZENITH: The purpose of this post-approval study is to evaluate the long-term safety and performance of the Zenith® TX2® TAA Endovascular Graft in the elective treatment of patients with descending thoracic aortic aneurysms or ulcers. Follow up for all enrolled subjects will be for 5 years. For more information, contact Gina at (309) 691-4410.